<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4936">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240886</url>
  </required_header>
  <id_info>
    <org_study_id>APX001-202</org_study_id>
    <secondary_id>2019-001386-33</secondary_id>
    <nct_id>NCT04240886</nct_id>
  </id_info>
  <brief_title>Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds</brief_title>
  <acronym>AEGIS</acronym>
  <official_title>A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amplyx Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amplyx Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal&#xD;
      infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp.,&#xD;
      and Mucorales fungi).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global Response</measure>
    <time_frame>End of Study Treatment or Day 42</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>Day 84</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Invasive Fungal Infections</condition>
  <arm_group>
    <arm_group_label>fosmanogepix (APX001)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fosmanogepix</intervention_name>
    <description>IV and oral fosmanogepix</description>
    <arm_group_label>fosmanogepix (APX001)</arm_group_label>
    <other_name>APX001</other_name>
    <other_name>E210</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, 18 years or older.&#xD;
&#xD;
          -  Patients with proven or probable IMI caused by Aspergillus spp. Patients who present&#xD;
             with IMI due to other filamentous fungi (eg, Scedosporium spp., Fusarium spp., and&#xD;
             Mucorales fungi such as Mucor spp. or Rhizopus spp.) may also be enrolled.&#xD;
&#xD;
          -  Have limited or no treatment options due to documented or anticipated resistance,&#xD;
             contraindication, intolerance, or lack of clinical response to SOC antifungal therapy,&#xD;
             as advocated by the relevant regional/country treatment guidelines.&#xD;
&#xD;
          -  Patients where the Investigator considers that there is a potential advantage of using&#xD;
             APX001 over current SOC (eg, broad spectrum of activity, emergence of IMI during&#xD;
             antifungal prophylaxis, activity against resistant mold pathogens, IV and PO&#xD;
             formulations, favorable DDI profile, favorable hepatic and renal safety profile, wide&#xD;
             tissue distribution including brain), and/or where the SOC antifungal therapy carries&#xD;
             significant risk of toxicity or treatment failure (eg, DDI risk, safety/toxicity risk,&#xD;
             site of infection not accessible by SOC).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refractory hematologic malignancy.&#xD;
&#xD;
          -  Chronic aspergillosis, aspergilloma, or allergic bronchopulmonary aspergillosis.&#xD;
&#xD;
          -  Treatment with systemic (PO, IV, or inhaled) mold active antifungal therapy for 120&#xD;
             hours immediately before initial dosing. Note: patients with invasive fungal infection&#xD;
             caused by a mold with documented resistance to or lack of coverage by the prior SOC in&#xD;
             question, may have received &gt;120 hours prior treatment and remain eligible for the&#xD;
             study.&#xD;
&#xD;
          -  Evidence of significant hepatic dysfunction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Susan Hazel</last_name>
    <phone>+1.858.436.7204</phone>
    <email>shazel@amplyx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Tel HaShomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>APX001</keyword>
  <keyword>APX001A</keyword>
  <keyword>fosmanogepix</keyword>
  <keyword>manogepix</keyword>
  <keyword>aspergillus</keyword>
  <keyword>aspergillosis</keyword>
  <keyword>covid</keyword>
  <keyword>covid19</keyword>
  <keyword>mold</keyword>
  <keyword>mould</keyword>
  <keyword>pulmonary aspergillosis</keyword>
  <keyword>pulmonary aspergillus</keyword>
  <keyword>galactomannan</keyword>
  <keyword>Karius</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>fusarium</keyword>
  <keyword>mucorales</keyword>
  <keyword>mucor</keyword>
  <keyword>rhizopus</keyword>
  <keyword>scedosporium</keyword>
  <keyword>fungal disease</keyword>
  <keyword>invasive fungal disease</keyword>
  <keyword>EORTC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

